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The Wnt/β-catenin pathway is one of the most conserved signaling pathways across species with 
essential roles in development, cell proliferation, and disease. Wnt signaling occurs at the protein 
level and via β-catenin-mediated transcription of target genes. However, little is known about the 
underlying mechanisms regulating the expression of the key Wnt ligand Wnt3a or the modulation of 
its activity. Here, we provide evidence that there is significant cross-talk between the dopamine D2 
receptor (D2R) and Wnt/β-catenin signaling pathways. Our data suggest that D2R-dependent cross-talk 
modulates Wnt3a expression via an evolutionarily-conserved TCF/LEF site within the WNT3A promoter. 
Moreover, D2R signaling also modulates cell proliferation and modifies the pathology in a renal 
ischemia/reperfusion-injury disease model, via its effects on Wnt/β-catenin signaling. Together, our 
results suggest that D2R is a transcriptional modulator of Wnt/β-catenin signal transduction with broad 
implications for health and development of new therapeutics.
Dopamine (DA) signaling, although traditionally studied in the central nervous system, is increasingly implicated 
in regulating the function of peripheral organs, including the pancreas and kidney1–5. Renal proximal tubule cells 
express components of the DA biosynthetic machinery as well as both D1-like (D1, D5) and D2-like (D2, D3, D4) 
DA receptors5–7. These cells therefore endogenously synthesize DA from circulating precursors, and utilize the 
newly synthesized DA locally, independent of the nervous system, to signal in an autocrine/paracrine manner6,8,9. 
This renal DA signaling regulates sodium transport to maintain fluid and electrolyte homeostasis and normal 
blood pressure7–10. Knockdown of any of the five DA receptor subtypes consequently results in increased blood 
pressure in mice4,10,11. Moreover, kidney-specific downregulation of the DA D2 receptor (D2R) increases oxidative 
stress and causes renal tubulointerstitial fibrosis and glomerulosclerosis11–14. Nevertheless, the precise mecha-
nisms of D2R signaling and their relationships to renal physiology and disease remain poorly understood.
D2-like DA receptors, including D2R, are class A G protein-coupled receptors (GPCRs) that signal 
via two downstream intracellular pathways: (i) G protein-dependent, arrestin-independent, and (ii) G 
protein-independent, arrestin-dependent pathways15–17. In the G protein-dependent pathway, D2R activation 
results in the recruitment of Gαi/o and ultimately leads to decreased levels of cyclic AMP (cAMP) synthesis16,18. 
In the G protein-independent, arrestin-dependent pathway, recruitment of arrestin 3 (β-arrestin-2) causes 
D2R internalization and inactivation of additional extracellular D2R signaling19. This β-arrestin-2-dependent 
pathway also leads to the recruitment of protein phosphatase 2 A (PP2A) and serine/threonine kinase AKT 
to the β-arrestin-2/D2R complex17,19,20. PP2A dephosphorylates AKT, leading to inactivation of AKT21. AKT 
regulates another key signaling kinase, glycogen synthase kinase β (GSK3β), through phosphorylation. In its 
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non-phosphorylated state, GSK3β is constitutively active, whereas AKT-induced phosphorylation inactivates 
GSK3β20. This D2R and β-arrestin-2-dependent AKT regulation of GSK3β has been increasingly implicated in 
neuronal physiology and pathophysiology, as well as in the mechanisms of both antipsychotic drugs and lithium 
action18,22–24. Notably, while D2R signals via G-protein-dependent and -independent pathways in response to 
stimulation, evidence also suggests that there may be an additional component of constitutive activity in both 
pathways25–27.
In addition to AKT’s roles in β-arrestin-2-dependent D2R signaling, this kinase may also contribute to the 
regulation of signaling within the Wnt/β-catenin pathway15,28,29. The Wnt/β-catenin pathway is nearly ubiqui-
tous across species and plays numerous critical roles in development and in both cell physiology and pathol-
ogy including cancer30. This signaling pathway is comprised of Frizzled (FZD) Wnt receptors and the LRP5/6 
co-receptor in association with Dishevelled, a scaffolding protein that activates a β-catenin destruction complex 
that includes Axin, Adenomatous polyposis coli (APC), and GSK3β28,31,32. In the absence of a stimulus, β-catenin, 
a transcriptional co-activator of Wnt target genes, is phosphorylated by active GSK3β and directed to the prote-
osomal pathway for degradation31. However, following activation of FZD/LRP5/6 by ligands, including Wnt3a, 
β-catenin translocates into the nucleus and binds to T-cell factor (TCF)/lymphoid enhancer-binding factor (LEF) 
proteins to stimulate Wnt target gene transcription30,31,33,34. Significantly, the ability of β-catenin to evade prote-
osomal destruction and initiate gene transcription is mediated by inactivation of GSK3β activity. GSK3β activity 
may be inhibited through phosphorylation of serine 9 or 21 through the actions of several kinases including 
AKT, protein kinase A (PKA), and integrin-linked kinase (ILK)32,35,36. Additionally, GSK3β activity is inhibited 
in response to treatment with growth factors including insulin/insulin-like growth factor I (IGF-I), nerve growth 
factor (NGF), or through inhibitory auto-phosphorylation32,37–42. Here, given AKT’s prominent role in D2R′s 
G protein-independent, arrestin-dependent pathway, we focus on D2R-mediated GSK3β inactivation via AKT 
phosphorylation15,43 and the resulting effects on β-catenin-driven changes in gene expression.
Since AKT plays important roles in both D2R and Wnt/β-catenin signaling pathways, we asked whether there 
is an AKT-dependent crosstalk between these two pathways where effects on AKT activity in one pathway may 
modulate downstream effects in the other. Moreover, we examined whether stimulation or inactivation of D2R 
signaling modulates β-catenin-mediated effects on transcription of Wnt pathway target genes. We established 
both in vitro cellular and in vivo animal models in both human and mouse renal proximal tubule cells to elucidate 
D2R′s role in modulating the Wnt/β-catenin signaling pathway, given the importance of both D2R and Wnt sign-
aling pathways in this cell type to kidney function including blood pressure regulation6,11,12. Using these models, 
we demonstrate a new paradigm by which stimulation of a GPCR, D2R, modulates Wnt/β-catenin signaling, 
Wnt3a expression, and cell proliferation in healthy and disease states, via its effects on gene transcription.
Results
β-arrestin-2-dependent AKT and GSK3β activities are modulated by D2R in renal proximal 
tubule cells. We examined dopaminergic, G protein-independent signaling in renal proximal tubule cells, 
since, in mice and humans, these cells endogenously express D2R7,13,14, as well as key proteins in the β-arres-
tin-2-dependent pathway including GSK3β, AKT, and PP2A44–46. However, to date, the extent of endogenous 
renal expression of β-arrestin-2 and its conservation across species remain unclear. We found that β-arrestin-2 
was endogenously expressed in mouse renal cortex, as well as in both mouse and human renal proximal tubule 
cells (Supplementary Fig. S1). Interestingly, comparison of β-arrestin-2 expression in human renal proximal 
tubule cells relative to Gapdh closely resembled β-arrestin-2 expression in mouse renal cortex (Supplementary 
Fig. S1).
We determined if mouse renal cortex, as well as mouse and human renal proximal tubule cells, can serve as 
novel experimental systems to further probe the β-arrestin-2-dependent arm of D2R signaling. Specifically, we 
explored the following signaling model: (1) D2R activation leads to dephosphorylation of active, phosphorylated 
AKT (P-AKT) and, (2) in the setting of decreased P-AKT, repressive phosphorylation of GSK3β is also reduced, 
thereby increasing GSK3β kinase activity (Fig. 1a). Consistent with this model, siRNA-induced D2R knockdown 
increased levels of P-AKT at the catalytic/stimulatory T308 phosphorylation site47,48 in mouse renal proximal 
tubule cells (Fig. 1b; original blots shown in Supplementary Fig. S2). We confirmed that these changes were 
due to effective D2R siRNA-mediated knockdown of D2R protein levels (Supplementary Fig. S3). To control for 
potential long-term adaptation to D2R downregulation, we also examined the effects of acute D2R blockade using 
sulpiride, an established D2R antagonist. Acute sulpiride treatment also increased P-AKT T308 levels similar 
to that found in the siRNA-mediated D2R knockdown (Fig. 1b). Conversely, treatment with the D2R agonist 
quinpirole decreased P-AKT T308 levels in these cells (Fig. 1b). Based on these data and the above model, we 
asked whether D2R-dependent changes in AKT phosphorylation produce corresponding alterations in GSK3β 
phosphorylation. siRNA-induced D2R knockdown increased levels of inactive phospho-GSK3β [P-GSK3β at the 
inhibitory S9 position40] (Fig. 1c, Supplementary Fig. S2); acute sulpiride treatment similarly elevated P-GSK3β 
levels (Fig. 1c). By contrast, acute treatment with D2R agonist quinpirole decreased P-GSK3β levels (Fig. 1c). We 
further validated our model in human renal proximal tubule cells. As in mouse renal proximal tubule cells, we 
found that either siRNA-mediated D2R knockdown or D2R antagonism by sulpiride increased phosphorylation 
of both AKT and GSK3β, while D2R stimulation by quinpirole decreased the phosphorylation of these kinases 
(Supplementary Fig. S4). Our data therefore suggest that these mechanisms are conserved across species.
D2R modulates β-catenin phosphorylation and transcriptional activity in the kidney and pan-
creas. In addition to its role as a mediator of D2R signaling, GSK3β is a major regulator of gene transcription 
via its phosphorylation of the nuclear transcriptional co-activator, β-catenin49,50. Phosphorylation of β-catenin by 
GSK3β increases β-catenin’s rate of proteasome-dependent degradation, thereby reducing β-catenin-dependent 
transcription of target genes15,31. Consistent with our findings that siRNA-mediated D2R knockdown decreased 
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Figure 1. AKT and GSK3β phosphorylation is modulated by D2R. (a) Model of D2R modulation of AKT/
GSK3β signaling. Binding of dopamine (DA) to the DA D2 receptor (D2R) recruits β-arrestin-2, a scaffolding 
protein, along with the kinase AKT and the phosphatase PP2A to the receptor independently of Gαi/o 
signaling. PP2A dephosphorylates AKT, inactivating the kinase. Phospho-AKT (P-AKT) is responsible for 
phosphorylating constitutively active GSK-3β, inactivating it. Thus, D2R-mediated AKT inactivation ultimately 
increases levels of active, non-phosphorylated GSK-3β. (b) D2R knockdown in mouse renal proximal tubule 
cells (mRPTCs) via D2R siRNA (72 hr) caused a 130% increase in AKT phosphorylation at the catalytic/
stimulatory T308 site, relative to the non-silencing (NS) siRNA control. Acute treatment with D2R antagonist 
sulpiride (1 µM, 6 hr) doubled AKT phosphorylation, relative to the vehicle control. D2R agonist quinpirole 
(1 µM, 24 hr) reduced AKT phosphorylation by 30% compared with the vehicle control. (c) D2R knockdown 
by D2R siRNA in mRPTCs caused a 150% increase in GSK3β phosphorylation (P-GSK3β) at the inhibitory 
S9 site, while acute sulpiride treatment also increased GSK3β phosphorylation by 50% compared with the 
respective controls. D2R activation by quinpirole decreased GSK3β phosphorylation by 20%, compared with 
vehicle. Results are represented as the ratio of P-AKT (T308)/total Akt, and P-GSK3β (S9)/total GSK3β and then 
normalized as percentage of NS siRNA or vehicle (% of control). All results are represented as the mean ± SEM 
conducted on n ≥ 3 separate experimental dates and performed in triplicate. *P < 0.05, ***P < 0.001; n = 3–4/
group; Student’s t-test.
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levels of active GSK3β (Fig. 1c), we also observed lower levels of phosphorylated β-catenin (P-β-catenin) in mouse 
renal proximal tubule cells when D2R expression was either knocked down via D2R siRNA or acutely blocked by 
sulpiride treatment (Fig. 2a). By contrast, D2R activation by quinpirole increased β-catenin phosphorylation in 
these cells (Fig. 2a). As with AKT and GSK3β, we replicated D2R-mediated effects on β-catenin phosphorylation 
in human renal proximal tubule cells (Supplementary Fig. S4).
On a functional level, we examined whether D2R′s effects on β-catenin phosphorylation modulate 
β-catenin-initiated transcription at TCF/LEF promoter sites. Using a luciferase-based TCF/LEF transcriptional 
activity assay, we found that decreased D2R signaling either through siRNA-induced D2R knockdown or acute 
sulpiride treatment elevated TCF/LEF reporter activity (Fig. 2b,c). By contrast, D2R activation by quinpirole 
decreased TCF/LEF transcriptional activity (Fig. 2b). Notably, while acute D2R blockade by sulpiride has 
a stronger stimulatory effect on TCF/LEF transcriptional activity relative to D2R siRNA knockdown, these 
D2R-mediated effects are weaker than direct Wnt3a stimulation (Fig. 2b,c). Overall, our data suggest that D2R 
mediates changes in transcription through its effects on β-catenin phosphorylation in renal proximal tubule cells.
We also examined whether D2R effects on β-catenin-mediated TCF/LEF transcriptional activity were gener-
alizable to other cell types and tissues beyond the kidney. We therefore determined whether D2R could modulate 
TCF/LEF transcriptional activity in INS-1E cells, an insulin-secreting rat pancreatic β-cell-derived cell line51. We 
chose this cell line since DA and D2R-dependent signaling may play important roles in β-cell physiology, serving 
as regulators of glucose-stimulated insulin secretion (GSIS)1,52–54. We used the D2R agonist bromocriptine since 
Figure 2. D2R modulates β-catenin phosphorylation and TCF/LEF activity. (a) siRNA knockdown of D2R 
(D2R siRNA) in mouse renal proximal tubule cells (mRPTCs) caused a 20% decrease in phosphorylated 
β-catenin (P-β-catenin, left panel) compared with the non-silencing (NS) siRNA control (72 hr). Acute sulpiride 
(D2R antagonist) treatment (1 µM, 6 hr) similarly reduced β-catenin phosphorylation by 25% compared with 
the vehicle control. Conversely, D2R agonism by quinpirole (1 µM, 24 hr) increased β-catenin phosphorylation, 
relative to the vehicle control (right panel). Results are represented as the ratio of P-β-catenin/total β-catenin, 
and then normalized as the percentage of NS siRNA or vehicle (% of control). (b) β-catenin-mediated TCF/
LEF luciferase reporter activity was significantly increased by 40% via siRNA-mediated D2R knockdown 
and decreased by 36% via 1 µM quinpirole treatment to stimulate D2R activity; results are normalized to 
the respective controls. (c) Acute sulpiride treatment significantly increased TCF/LEF promoter activity by 
80%, while direct stimulation by Wnt3a (100 ng/ml, 2 hr) more than doubled (224%) TCF/LEF promoter 
activity, relative to vehicle control. All data are represented as the mean ± SEM conducted on n ≥ 3 separate 
experimental dates and performed in triplicate. *P < 0.05, **P < 0.01; n = 4–5/group, Student’s t-test for (a,b); 
one-way ANOVA and Holm-Sidak post-hoc test for (c).
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bromocriptine is a highly potent and effective modulator of GSIS in INS-1E cells55,56. Consistent with our data in 
the kidney, we found that overnight treatment of INS-1E cells with bromocriptine significantly inhibited TCF/
LEF transcription (Supplementary Fig. S5). These data suggest that D2R′s putative role as a negative regulator of 
β-catenin-mediated TCF/LEF transcriptional activity is conserved across cell types and species.
DRD2 single nucleotide polymorphisms (SNPs) decrease β-catenin phosphorylation in human 
renal proximal tubule cells. The DRD2 gene encoding D2R is highly polymorphic. Several DRD2 SNPs 
modify levels of D2R expression, including those expressed in human renal proximal tubule cells13. We focused 
on the combination of two common SNPs in the human DRD2 gene, rs6276 and rs6277 (Fig. 3a), previously 
shown to increase vulnerability to renal inflammation independently of blood pressure13. We found that the 
presence of these two SNPs significantly decreased both mRNA and protein expressions of D2R in human renal 
proximal tubule cells relative to control cells without the SNPs (Fig. 3b). Consistent with our D2R siRNA data 
in mouse proximal renal tubule cells (Fig. 2a), the presence of these DRD2 SNPs also diminished the levels of 
P-β-catenin (Fig. 3b). Conversely, increasing levels of D2R expression in the SNP background via heterologous 
D2R overexpression led to a concomitant increase in P-β-catenin (Fig. 3c).
D2R modulates cell proliferation in vitro and in vivo via Wnt3a. There is a well-known relationship 
between levels of β-catenin and its effects on cellular proliferation. As levels of non-phosphorylated β-catenin 
rise, the resulting elevation in β-catenin-driven transcription increases cell proliferation57–59. Consistent with 
these reports, we found that Ki-67, a marker of cell proliferation60, was increased 2.7-fold in human renal prox-
imal tubule cells containing rs6276 and rs6277 SNPs (Fig. 3d). Similarly, siRNA-induced D2R knockdown also 
increased cell proliferation in mouse renal proximal tubule cells (Supplementary Fig. S6). These data suggest a 
relationship not only between D2R and β-catenin phosphorylation, but also between D2R and cell proliferation.
Building upon our in vitro cellular data, we developed an in vivo model to further study the relationship 
between D2R and cell proliferation. In vivo renal-selective D2R knockdown by the renal subcapsular infusion 
of D2R siRNA significantly decreased D2R expression (Supplementary Fig. S7A), and diminished levels of 
P-β-catenin (Fig. 4a). Consistent with our earlier in vitro observations in DRD2 SNP-containing cells (Fig. 3), we 
observed an increase in the number of Ki-67-positive cells in renal sections (Fig. 4b,c). D2R knockdown was also 
associated with increased Ki-67 expression at the mRNA level in renal cortex (Fig. 4c). By contrast, in vivo rescue 
of D2R expression via retrograde ureteral infusion of D2R adeno-associated virus (AAV) increased D2R expres-
sion 10-fold (Supplementary Fig. S7b) and reversed the effects of renal-selective D2R knockdown on β-catenin 
phosphorylation and Ki-67 mRNA and protein expressions (Fig. 4d–f).
Since Wnt3a is a powerful mediator of physiological and pathological cell proliferation via signaling through 
β-catenin61–63, we determined whether D2R′s effects on cell proliferation are modulated through Wnt3a. We 
found that in vitro D2R siRNA knockdown increased Wnt3a expression 2.5-fold, while D2R activation with 
quinpirole decreased Wnt3a expression by 80% in mouse renal proximal tubule cells (Fig. 5a). In vivo knockdown 
of D2R by the renal subcapsular infusion of D2R siRNA increased Wnt3a expression to an even greater degree 
(4-fold increase; Fig. 5b). Moreover, in human renal proximal tubule cells with the DRD2 rs6276 and rs6277 SNPs, 
the decreased D2R expression was associated with increased Wnt3a mRNA and protein levels (Fig. 5c). Similarly, 
acute D2R antagonism by sulpiride significantly elevated Wnt3a protein expression in wild-type (non-SNPs) 
human renal proximal tubule cells, controlling for potential confounding compensatory effects due to lower levels 
of D2R expression (Fig. 5d). By contrast, treatment of the wild-type (non-SNPs) human renal proximal tubule 
cells with D2R agonist quinpirole reduced Wnt3a protein levels (Fig. 5d). Although our data strongly suggested 
links between D2R-mediated changes in both Ki-67 and Wnt3a expression, we sought to determine whether these 
D2R effects on proliferation are mediated via Wnt3a. Consequently, we knocked down Wnt3a via siRNA in the 
human renal proximal tubule cells with D2R SNPs and, along with the expected decreases in Wnt3a protein, we 
also observed significantly decreased expression of Ki-67 (Fig. 5e). To examine the effects of D2R signaling on 
Wnt3a expression in vivo, we knocked down the renal expression of D2R in vivo via renal subcapsular injection of 
D2R siRNA. We found an increase in the mRNA expression of Wnt3a, consistent with our model. Renal-selective 
rescue of D2R function in the siRNA-injected mice by concurrent AAV overexpression of D2R reduced this 
Wnt3a increase (Supplementary Fig. S8). Nevertheless, because siRNA-induced D2R knockdown and overex-
pression were sequential, it is possible that remaining increases in Wnt3a expression caused by the original D2R 
knockdown led to signaling changes that affected Wnt3a expression that subsequent D2R overexpression was 
unable to override.
We determined whether D2R modulation of Wnt3a signaling occurred in cell types outside the kidney by 
again examining pancreatic β cell-derived INS-1E cells. We found that INS-1E cells responded to Wnt3a in a 
dose-dependent manner by progressively increasing TCF/LEF-mediated transcription (Supplementary Fig. S9a). 
Furthermore, D2R stimulation by agonist bromocriptine significantly reduced the Wnt3a-induced increase in 
TCF/LEF signaling (Supplementary Fig. S9b). We confirmed these findings, showing that D2R stimulation with 
additional agonists including DA or quinpirole also significantly diminished the Wnt3a-induced increase in TCF/
LEF activity (Supplementary Fig. S9b). These data suggest that the links between D2R and Wnt3a signaling and 
the resulting changes in gene transcription are conserved across mammalian cell types.
Wnt3a expression is regulated by β-catenin and TCF/LEF signaling. In freshwater polyp Hydra spe-
cies including Hydra magnipapillata and Hydra vulgaris, there is evidence suggesting that Hydra Wnt3 (HyWnt) 
transcription is modulated by cis-regulation through β-catenin signaling64. The presence of a TCF/LEF autoreg-
ulatory element within the HyWnt promoter allows β-catenin to further increase HyWnt expression and thus 
potentiate Wnt signaling64. Based on D2R′s effects on β-catenin phosphorylation and TCF/LEF transcription, we 
asked whether similar cis-regulatory elements are used to regulate mammalian Wnt3a expression. To examine this 
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Figure 3. DRD2 SNP cluster rs6276, rs6277 decreases D2R expression, modulates β-catenin phosphorylation 
and increases cell proliferation in vitro. (a) Schema of the relative positions of the SNPs rs6276 and rs6277 
in the human DRD2 gene. (b) The joint presence of SNPs rs6276 and 6277 in human renal proximal tubule 
cells reduced D2R mRNA levels by 50% (left panel) along with a concomitant 50% decrease in D2R protein 
levels (middle panel). Levels of phospho-β-catenin (P-β-catenin) also decreased by 40%, relative to control 
cells without these SNPs (right panel). Insets show representative immunoblots. (c) Transfection of the DRD2 
SNP-containing cells with a human DRD2 plasmid without the SNPs significantly boosted D2R mRNA levels 
30-fold (left panel), as well as D2R protein levels 2.2-fold (middle panel). Increasing wild-type D2R expression 
in these cells also increased P-β-catenin levels (right panel, inset showing western blot), relative to the empty 
vector control. (d) Presence of DRD2 SNPs rs6276 and rs6277 led to a 2.7-fold increase in cellular proliferation 
as indicated by the Ki-67 marker. All data are represented as the mean ± SEM conducted on n ≥ 3 separate 
experimental dates and performed in triplicate. **P < 0.01, ***P < 0.001; n = 3–4/group; Student’s t-test.
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Figure 4. D2R expression modulates renal cell proliferation in vivo. (a) Kidney-selective D2R knockdown 
in vivo via siRNA (D2R siRNA) decreased β-catenin phosphorylation (P-β-catenin) in mouse renal cortex 
by 40% relative to the NS siRNA control. (b) D2R siRNA knockdown also increased the expression of the 
cell proliferation marker Ki-67. Merged confocal images show Ki-67 (red) and DAPI nuclear staining (blue); 
magenta shows colocalization. Scale bar = 50 µm. (c) Quantification of the Ki-67-positive cells in the renal 
cortex revealed significant increases in the number of Ki-67-positive cells/field along with a 3-fold increase 
in Ki-67 mRNA following D2R siRNA treatment compared with control mice treated with the NS siRNA 
control; n ≥ 4 for all groups. (d) Rescue of D2R expression via AAV-mediated renal D2R overexpression (D2R 
AAV) reversed the effects of in vivo D2R siRNA on β-catenin phosphorylation by raising P-β-catenin levels 
(left panel); inset shows a representative immunoblot. Alongside is the schedule for the respective siRNA and 
AAV treatments. Ki-67 expression was decreased in the D2R AAV-treated kidneys by 50% in comparison with 
mice treated with control AAV (CAAV, right panel). (e) Confocal immunofluorescence imaging of the D2R 
AAV rescue of D2R siRNA knockdown showed a 2-fold decrease in Ki-67-positive cells. Merged confocal 
images show DAPI (blue) and Ki-67 (red); magenta shows colocalization. Scale bar = 50 µm. (f) Accompanying 
quantification of Ki-67-positive cells in response to D2R AAV rescue of D2R siRNA knockdown. All data are 
represented as the mean ± SEM. *P < 0.05, **P < 0.01; n = 3–4/group; Student’s t-test.
8Scientific RepoRtS |         (2019) 9:16861  | https://doi.org/10.1038/s41598-019-52528-4
www.nature.com/scientificreportswww.nature.com/scientificreports/
Figure 5. D2R modulates Wnt3a expression. (a) D2R siRNA (72 hr) increased Wnt3a mRNA levels 2.6-
fold (left panel) in mouse renal proximal tubule cells. Conversely, the D2R agonist quinpirole (1 µM, 24 hr) 
decreased Wnt3a expression by 70% in these cells (right panel). (b) Kidney-selective D2R knockdown in vivo 
via renal subcapsular D2R siRNA infusion similarly increased Wnt3a expression 4-fold in mouse renal cortex 
(left panel). (c) Human renal proximal tubule cells with D2R expression-reducing SNPs rs6276 and rs6277 had 
increased Wnt3a mRNA levels (2.9-fold, left panel) and protein expression (1.5-fold, right panel) in the setting 
of diminished D2R expression, relative to cells without these SNPs (wild-type, WT). (d) D2R agonist quinpirole 
(1 µM, 24 hr) decreased Wnt3a protein by 44% in the SNP-free wild-type (WT) human renal proximal tubule 
cells compared with vehicle. Acute treatment with D2R antagonist sulpiride (1 µM, 6 hr) significantly increased 
Wnt3a protein by 180% in the WT human renal proximal tubule cells compared with vehicle. (e) Wnt3a 
knockdown via siRNA (Wnt3a siRNA) significantly decreased Wnt3a protein levels (right panel) in human 
renal proximal tubule cells expressing SNP cluster rs6276 and 6277 and partially attenuated the increased levels 
of proliferation in these cells, as indicated by the decrease in Ki-67 mRNA (right panel). All data are represented 
as the mean ± SEM. For Panels (a,c–e): all cell experiments were conducted on n ≥ 3 separate experimental 
dates and performed in triplicate. For Panel (b): all animal experiments used n = 4–5 animals per group; 
measurements were performed in triplicate. *P < 0.05, **P < 0.01, ***P < 0.001; Student’s t-test.
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possibility, we searched for potential TCF/LEF binding sites in the promoter region of the mammalian WNT3A 
gene. We constructed a phylogenetic tree of human WNT3A and discovered marked conservation across several 
species: human, mouse, rat, chicken, and zebrafish (Fig. 6a). Among the conserved regions, there were multiple 
TCF/LEF binding sites in the 5 kb promoter region upstream of the WNT3A transcriptional start site (TSS) of 
human, rat, mouse, and chicken WNT3A but only two TCF/LEF binding sites in zebrafish (Fig. 6b). Nevertheless, 
the zebrafish TCF/LEF site at position −1413 is well-conserved across all species examined except for the rat. 
These data suggest that, as in Hydra, Wnt3a expression may be regulated through β-catenin’s actions on conserved 
TCF/LEF binding sites within the WNT3A promoter. We therefore created a reporter of WNT3A transcription 
consisting of a portion of the WNT3A promoter that included the conserved TCF/LEF site fused to luciferase 
(Fig. 6c). We used the luminescence readout from the reporter to determine the potential contribution of this site 
to levels of WNT3A transcription by mutating the conserved TCF/LEF site to block β-catenin-mediated changes. 
We found that mutation of the TCF/LEF site significantly diminished WNT3A promoter activity (Fig. 6c). These 
results suggest that an important role for TCF/LEF sites within the WNT3A promoter may be to autoregulate 
Wnt3a expression. Such sites may therefore potentially contribute to D2R′s effects on Wnt3a expression, given 
D2R′s ability to modulate β-catenin activity.
Strikingly, our analyses of putative TCF/LEF sites revealed that the DRD2 promoter also contains 
cis-regulatory TCF/LEF sites. We conducted a phylogenetic analysis of conserved TCF/LEF binding sites within 
the 5 kb promoter region upstream of the TSS of the human DRD2 gene and its orthologs in mouse, rat, chicken, 
and zebrafish. Similar to WNT3A, along with several TCF/LEF sites within the respective promoter regions, there 
is a highly conserved TCF/LEF site evident in all species except for the rat (Fig. 6d). These results suggest that 
β-catenin may act as a convergence point to balance D2R and Wnt3a-driven signals.
We examined the functional relevance of the conserved TCF/LEF binding site within the DRD2 promoter, pre-
dicting that stimulation of the Wnt3a signaling pathway would upregulate D2R expression. Indeed, we observed 
that treatment with either LiCl or recombinant Wnt3a protein, strong drivers of Wnt3a pathway signaling, signif-
icantly increased D2R mRNA expression (Fig. 6e).
Increased D2R expression modifies cell proliferation in the ischemia/reperfusion-injury model. 
We investigated the relevance of D2R′s modulation of Wnt3a expression and cell proliferation within a dis-
ease context using the ischemia/reperfusion-injury (I/R) model of acute kidney injury. We chose this model 
system given the critical role played by cell proliferation in the associated pathology65,66. We observed a 3-fold 
increase in Wnt3a mRNA expression and 25% increase in Wnt3a protein expression following I/R, along with 
increased Ki-67 mRNA levels (Fig. 7a), consistent with established evidence of increased cell proliferation fol-
lowing reperfusion66,67. We also found increased nuclear co-localization between Ki-67 and β-catenin after rep-
erfusion, demonstrating that the Wnt/β-catenin pathway is active in the proliferating cells (Fig. 7b). By contrast, 
AAV-mediated D2R overexpression immediately before the reperfusion period almost completely prevented the 
I/R-induced increase in Wnt3a mRNA and protein expression (Fig. 8a). Increasing D2R expression just prior 
to reperfusion also significantly diminished cell proliferation based on Ki-67 mRNA quantification (Fig. 8a). 
Confocal microscopy imaging of the D2R-overexpressing tissue showed a decrease in the nuclear co-localization 
between Ki-67 and β-catenin (Fig. 8b). These data further suggest an important link between D2R and Wnt sig-
naling in vivo. Overall, our results show that boosting D2R signaling can negatively modulate Wnt3a-mediated 
cell proliferation induced by I/R and thereby modify one of the main contributors to pathologic change within 
this disease model.
Discussion
Both DA and Wnt signaling pathways are nearly ubiquitous across organ systems and species. These signaling 
systems are integral drivers of physiological processes across development and have been implicated in a diverse 
array of diseases ranging from cancer to schizophrenia15,29,57,63. Yet, despite decades of study, many fundamen-
tal questions still remain concerning the mechanisms by which these two pathways are regulated and whether 
they intersect in specific cellular states or cell types. For example, though the sequence of signaling within the 
Wnt/β-catenin pathway has been thoroughly mapped out, the mechanisms regulating the expression of key Wnt 
ligands such as Wnt3a remain poorly understood. Similarly, downstream of the DA receptors, the precise phys-
iological relevance of signaling via the G protein-dependent versus -independent pathways is largely unknown. 
Last but not least, despite sharing several common signaling components15, it has remained unclear whether DA 
and Wnt pathways modulate one another and, if so, under what contexts.
While DA has been studied primarily in the central nervous system, it also plays important functions in 
diverse peripheral organs including the kidney, pancreas, and gut6,68,69. These organs have the capacity to synthe-
size DA, which then signals locally in an autocrine and/or paracrine manner through DA receptors, including 
D2R52,53,70. In the pancreatic β-cell, D2R signaling is implicated as a negative modulator of insulin secretion3,52. 
In the kidney, renal DA regulates systemic blood pressure, in part, through D2-like receptor signaling10,12, via its 
effects on fluid and electrolyte balance as well as regulation of the secretion/metabolism of hormones such as 
aldosterone and angiotensin II6,11,70. Moreover, genetic hypertension is associated with alterations in DA produc-
tion and D2-like receptor function6. Likewise, Wnt/β-catenin pathway signaling is essential in both kidney and 
pancreatic development and is implicated in the pathophysiology associated in both organs71,72.
Here, we present evidence that signaling through D2R modulates the Wnt pathway. We provide a putative 
mechanism for this crosstalk: D2R-dependent β-arrestin-2 signaling leads to diminished phosphorylation of 
β-catenin. This in turn promotes β-catenin’s translocation to the nucleus and increased TCF/LEF-mediated 
transcription within the Wnt/β-catenin pathway, including Wnt3a itself. In addition to G protein-dependent 
signaling, D2R also signals through β-arrestin-2, a protein long known to facilitate receptor internalization23,73. 
The β-arrestin-2 pathway is an important route for further downstream signaling involving AKT and GSK-3β 
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Figure 6. Modulation of Wnt3a expression via a conserved TCF/LEF promoter site. (a) Phylogenetic tree of 
WNT3A across multiple species: human, mouse, rat, chicken, and zebrafish. The WNT3A exons were used 
to construct the phylogenetic tree. Evolutionary distances in the units of base substitutions per site were 
calculated using the maximum composite likelihood method. The phylogenetic tree was then constructed 
using the Neighbor-Joining method with the sum of branch lengths = 0.645. (b) Binding site analysis of 
aligned human, mouse, rat, chicken, and zebrafish WNT3A promoter sequences highlighting conserved 
β-catenin-binding TCF/LEF sites within the 5 kb region upstream of the transcriptional start site (TSS). 
(c) Schematic representation of our luciferase reporter of TCF/LEF-dependent WNT3A transcription 
(left panel). The reporter construct consists of a selected segment of the human WNT3A promoter region 
containing a highly conserved TCF/LEF site upstream of the Gaussia luciferase gene. We show two variants 
of the reporter: one containing the wild-type (WT) TCF/LEF site (Human-WT) and another where the TCF/
LEF site was inactivated by mutation (Human-Mut). Upon expression of a WNT3A transcriptional reporter 
in human renal proximal tubule cells, the Human-Mut reporter demonstrated significantly decreased 
WNT3A promoter activity compared with the WT control (right panel). The data were normalized to alkaline 
phosphatase expression. *P < 0.05; Student’s t-test. (d) Binding site analysis of aligned human, mouse, rat, 
chicken, and zebrafish DRD2 promoter sequences highlighting conserved β-catenin-binding TCF/LEF sites 
within the 5 kb region upstream of the TSS. (e) Treatment with either LiCl (25 mM, 24 hr) or recombinant 
Wnt3a (100 ng/ml, 24 hr) significantly increased D2R mRNA expression. Data are expressed as mean ± SEM 
of 3 experiments conducted on separate experimental dates and performed in triplicate. *P < 0.05; Student’s 
t-test (c). *P < 0.05, ***P < 0.001; one-way ANOVA, Holm-Sidak post-hoc test (e).
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kinases, critical signaling molecules implicated in numerous cellular functions including metabolism and pro-
liferation17,19–21,74. Though the original β-arrestin-2 studies were conducted largely in rodent brain and in vitro, 
we show that these β-arrestin-2-dependent D2R signaling pathways are present in both human and rodent renal 
cells, suggesting that D2R′s capacity to modulate AKT phosphorylation and activity is a more general princi-
ple that is conserved across tissues and species. Our data also establish a model where D2R signaling via the 
β-arrestin-2-dependent pathway modulates TCF/LEF promoter activity through its ability to modify β-catenin’s 
degradation and capacity to translocate into the nucleus. This represents an important new mechanism by which 
GPCRs like D2R may utilize G protein-independent, β-arrestin-2-dependent signaling to modulate transcription 
via interactions with the Wnt/β-catenin pathway.
Analogous to the kidney, we found that D2R activity also modulates Wnt3a-dependent β-catenin transcrip-
tional activity in INS-1E cells, a rat pancreatic β-cell line, suggesting that D2R′s ability to modulate Wnt sign-
aling is conserved across both species and tissues. There is precedent for GPCR modulation of Wnt/β-catenin 
signaling in β-cells. Earlier work demonstrated that agonists of glucagon-like peptide-1 receptor, a GPCR, 
could enhance β-cell Wnt signaling75, ultimately leading to changes in β-cell mass through its actions on TCF/
LEF-based transcription75,76. Additionally, Min and colleagues reported that the effects of D2R on neuronal Wnt 
signaling could also be agonist-independent and based, in part, on direct physical interactions between D2R and 
β-catenin25. This raises the possibility that at least some of this signaling is constitutive. Indeed, our data in renal 
cells using D2R blockade by sulpiride or siRNA-mediated D2R knockdown indicate some degree of constitutive 
(i.e., agonist-independent) regulation of Wnt signaling which is consistent with this earlier work25. Moreover, in 
Figure 7. Wnt3a expression and cell proliferation increase in an ischemia/reperfusion-injury disease model. 
(a) Ischemia/reperfusion-injury (I/R) caused a 200% increase in Wnt3a mRNA levels (left panel) and 50% 
increase in Wnt3a protein levels (middle panel) in mouse renal cortex. There was an accompanying 55% 
increase in expression of the Ki-67 cell proliferation marker compared with the control (right panel). Alongside 
is the schedule for the I/R treatment. (b) Representative confocal immunofluorescence images of mouse renal 
cortex following I/R demonstrated increased nuclear Ki-67 (red), nuclear β-catenin (green), and increased 
nuclear co-localization of Ki-67 and β-catenin with DAPI (blue). Merged images: blue = DAPI, red = Ki-
67, green = β-catenin, overlap = white); arrowheads indicate nuclear overlap among Ki-67, β-catenin, and 
DAPI signals. Scale bar = 50 µm. All data are represented as the mean ± SEM using 4 animals per group. All 
measurements were performed in triplicate. *P < 0.05, **P < 0.01, ***P < 0.001; Student’s t-test.
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addition to β-arrestin-2-dependent GPCR signaling, there is increasing evidence that inhibitory heterotrimeric 
Gαi/o proteins are also involved in Wnt-induced responses77–79. Therefore, we propose that D2R stimulation may 
also trigger recruitment and activation of sufficient Gαi/o to displace these proteins from FZD receptors, leading 
to a reduced G protein-dependent Wnt-stimulated response. Such a model may provide an additional explanation 
for our findings demonstrating that D2R stimulation by agonists including DA, quinpirole and bromocriptine 
reduces Wnt-dependent signaling in β-cells.
We further dissected D2R-mediated effects on TCF/LEF transcriptional activity in human renal proximal tubule 
cells, taking advantage of DRD2 SNPs that negatively regulate endogenous D2R expression and function13,80–82. 
Several SNPs within the human DRD2 gene have been associated with clinically relevant conditions including 
elevated blood pressure and essential hypertension13. Moreover, a recent study in an Asian Indian population with 
type 2 diabetes found that a SNP that decreased D2R expression also conferred susceptibility to chronic diabetic 
nephropathy83. Similarly, the combination of two highly prevalent DRD2 SNPs, rs6276 and rs6277, decreased 
D2R expression as a consequence of diminished D2R mRNA stability as well as via decreased receptor avail-
ability and affinity13,80–82. We found that the combined effects of these two DRD2 SNPs also diminished levels 
of phosphorylated β-catenin, presumably freeing more β-catenin to successfully evade degradation and thus to 
stimulate transcription of Wnt/β-catenin pathway target genes. Given the Wnt/β-catenin pathway’s roles in medi-
ating cell proliferation, our results suggest that D2R signaling may utilize such an intersection with Wnt sign-
aling to modulate β-catenin and Wnt-dependent cell proliferation. Consistent with this, recent studies suggest 
that D2-like receptor activation inhibits cellular proliferation while, conversely, its inhibition increases cellular 
Figure 8. D2R overexpression partially reverses increased Wnt3a expression and cell proliferation in response 
to ischemia/reperfusion injury. (a) AAV-mediated D2R overexpression (D2R AAV) in mouse kidney prior to 
reperfusion caused a 70% decrease in Wnt3a mRNA levels (left panel) and a 40% decrease in Wnt3a protein 
levels (middle panel). There was also a 30% decrease in Ki-67 mRNA in the renal cortex relative to the control 
AAV vector (right panel). Alongside is the schedule for the respective ischemia/reperfusion (I/R) and AAV 
treatments. (b) Representative confocal immunofluorescence images of mouse renal cortex following AAV-
mediated D2R overexpression in an I/R model of acute renal injury. There was decreased nuclear Ki-67 
(red), nuclear β-catenin (green) and decreased nuclear co-localization of Ki-67 and β-catenin with DAPI 
(blue). Merged images: blue = DAPI, red = Ki-67, green = β-catenin, overlap = white); arrowheads indicate 
nuclear overlap among Ki-67, β-catenin, and DAPI signals. Scale bar = 50 µm. All data are represented as 
the mean ± SEM using 4 animals per group. All measurements were performed in triplicate. *P < 0.05, 
***P < 0.001, Student’s t-test.
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proliferation84–87. Furthermore, in pancreatic β-cells, pharmacological D2R inhibition not only increases cell pro-
liferation, but also decreases cell de-differentiation, collectively leading to increased β-cell mass85. Given D2R′s 
ability to modify β-catenin-mediated TCF/LEF transcription, we propose that the interconnections between D2R 
and Wnt signaling may be critical in modulating cell proliferation under physiological circumstances, at least in 
the cell types we assayed (human and mouse renal proximal tubule cells and rat pancreatic β-cells [INS-1E]). 
Moreover, D2R′s inhibitory effects on proliferation may be a regulatory mechanism by which cells avoid uncon-
trolled expansion.
Given the interconnections between D2R and Wnt/β-catenin signaling pathways, we investigated whether 
Wnt3a, one of the primary ligands for the Wnt receptor FZD (FZD2 in kidney), is also implicated in these 
processes. Indeed, Wnt3a has been shown to mediate cell proliferation88,89. We used several complementary 
approaches to demonstrate significant increases in Wnt3a expression in response to reduced D2R expression 
including D2R knockdown in mouse renal proximal tubule cells in vitro and renal cortex in vivo, as well as human 
renal proximal tubule cells where D2R expression is reduced by the presence of SNPs. Together, our results sug-
gest an important relationship between D2R signaling and Wnt3a expression. Furthermore, these data describe 
a possible new mechanism where alterations in D2R expression may trigger a corresponding change in Wnt3a 
levels which then alters β-catenin-mediated TCF/LEF transcription in processes including cell proliferation.
Prior work in Hydra demonstrated that TCF/LEF sites within the promoter of the Hydra Wnt3a ortholog, 
HyWnt3, regulated Wnt3 expression64. Nevertheless, it remained unclear whether such a regulatory mechanism 
for Wnt3a expression was generalized across species, especially in mammals. We now show that the promoters 
corresponding to Wnt3a orthologs contain numerous TCF/LEF sites across multiple species from zebrafish to 
mice and humans. Our findings demonstrate remarkable conservation of these regulatory elements across species 
and suggest β-catenin is a positive modulator of Wnt3a expression. However, this also leads to the question: how 
do cells terminate such a positive feedback mechanism for Wnt3a expression to avoid uncontrolled Wnt3a signa-
ling that may ultimately be detrimental to overall cellular viability and/or lead to uncontrolled cell proliferation?
We propose that D2R may contribute to the regulatory mechanisms that limit Wnt3a′s capacity to induce its own 
increased expression and thus prevent uncontrolled cell proliferation. One potential mechanism may be D2R′s ability 
to negatively regulate β-catenin nuclear translocation via its actions on AKT and GSK3β. With our discovery that D2R 
itself contains evolutionarily-conserved TCF/LEF sites in its promoter, this suggests a model where D2R expression 
may also be promoted following an initial Wnt3a-induced boost in β-catenin-mediated transcription (Fig. 9). We 
confirmed this model, showing that direct stimulation of the Wnt3a pathway via treatment with recombinant Wnt3a 
or LiCl causes significant increases in D2R transcription. We assert that this rise in D2R levels dampens subsequent 
increases in Wnt3a levels and thus keeps processes such as cell proliferation in check. Such a model of reciprocal D2R 
and Wnt3a signaling at the transcriptional level establishes the importance of D2R signaling as a novel modulator of 
Wnt/β-catenin signaling under physiological conditions (Fig. 9). Furthermore, our data showing that LiCl treatment 
significantly increases D2R expression may be relevant not only in renal cells but also in neurons, suggesting a new 
mechanism for LiCl’s action in the central nervous system.
We also investigated a potential role for renal D2R signaling in a disease context via the I/R model of acute kid-
ney injury65,66,90. Classically, induction of renal ischemia followed by reperfusion leads to increased cell prolifera-
tion and subsequent development of injury, hypertrophy and decreased overall renal function4,65,67. Significantly, 
we found that acute renal injury in the I/R model increased Wnt3a expression and led to increased nuclear local-
ization of both Ki-67 and β-catenin in injured tissue, indicating the involvement of the Wnt/β-catenin path-
way in injury-induced cell proliferation. Moreover, AAV-mediated overexpression of D2R diminished this 
injury-induced cell proliferation and reduced the increase in Wnt3a expression within the injured tissue. Our data 
are consistent with earlier work implicating elevated Wnt3a expression in renal injury91. This is also consistent 
with our previous results showing that increasing renal D2R decreases the extent of ischemic injury, ameliorating 
both renal function and normalizing blood pressure4. Conversely, silencing of D2R was itself sufficient to induce 
renal injury as demonstrated by increased levels of kidney injury marker KIM-1, and this effect was reversed by 
D2R overexpression4. These data further suggest the importance of renal D2R signaling in maintaining normal 
renal physiology, as well as in acute renal injury. Together, our results suggest that D2R signaling and its inter-
actions with the Wnt/β-catenin pathway may play critical roles in modulating the extent of renal injury and that 
modifying D2R expression may serve as a novel therapeutic avenue for preventing the progression of kidney 
disease.
At present, much of our understanding of D2R and GPCR signaling more generally derives from its acute 
effects on downstream G proteins. While G protein-dependent signaling is often rapid, occurring over seconds 
and minutes, here we show that the G protein-independent, β-arrestin-2-dependent arm of D2R signaling may 
also play important roles in cellular physiology and pathophysiology on a longer time scale via its effects at the 
transcriptional level. This suggests a paradigm where D2R utilizes multiple highly conserved downstream sign-
aling pathways to selectively induce both acute changes in signaling and concurrent longer-term changes via its 
effects on transcriptional regulation. Such GPCR-modulated effects on transcription may be quite relevant phys-
iologically to regulate cell proliferation or differentiation during development as well as in the context of disease 
states including diabetes or hypertension. There is precedent for GPCR regulation of transcription through the 
receptors’ effects on intracellular cAMP levels via G protein-dependent signaling92. By modulating cAMP produc-
tion through recruitment of G proteins such as Gαs or Gαi, GPCRs may change the activity of cAMP-dependent 
gene transcription factors including cAMP response element binding proteins (CREB-BPs), and thus alter lev-
els of gene transcription93. Such a mechanism may have direct implications for β-catenin-mediated transcrip-
tion since CREB-BPs are also constituents of the β-catenin/TCF transcriptional complex94. Therefore, for a 
Gαi/o-coupled receptor like D2R, G protein and cAMP-dependent signaling may synergize with D2R′s effects on 
β-catenin phosphorylation to ultimately determine the efficacy of β-catenin/TCF/LEF-mediated transcriptional 
regulation.
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conclusions
We show that D2R modulates signaling through the Wnt/β-catenin pathway, in part, through its effects 
on Wnt3a expression. Our work presents a novel mechanism by which a GPCR, D2R, works through the 
β-arrestin-2-dependent pathway to modulate transcription. Furthermore, given the ability of D2R-blocking 
drugs, such as antipsychotic medications to induce metabolic syndrome consisting of disturbances such as diabe-
tes and hypertension95, our findings may shed important new light on the underlying mechanisms responsible for 
Figure 9. Model of cross-talk between D2R and Wnt/β-catenin pathways, and Wnt3a transcriptional 
regulation. We propose the following mechanism by which D2R and Wnt3a reciprocally regulate their 
expression: (a) Wnt3a stimulation of the Frizzled (FZD) receptor/LRP5/6 complex leads to less β-catenin 
degradation via the destruction complex and proteasomal pathway. Instead, more β-catenin is available for 
translocation into the nucleus where it increases Wnt3a transcription and expression via a TCF/LEF site within 
the Wnt3a promoter. This leads to a positive feedback loop that amplifies further Wnt3a signaling. (b) Increased 
nuclear translocation of β-catenin also upregulates D2R expression through TCF/LEF sites within the D2R 
promoter. Increased D2R expression leads to more β-catenin phosphorylation, resulting in enhanced β-catenin 
proteasomal degradation and therefore less β-catenin nuclear translocation. This ultimately inhibits further 
β-catenin-mediated Wnt3a transcription to maintain cellular homeostasis.
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these profound and previously unanticipated effects on cellular physiology. These studies therefore open the door 
to a broader understanding of intracellular signaling and its implications in health and disease.
Materials and Methods
Compounds. The drugs used in the present study were purchased from Sigma-Aldrich (St. Louis, MO), 
unless indicated otherwise: plasmocin (Fisher Scientific, Hampton, NH); EGF, dexamethasone, triiodothyro-
nine, insulin-transferrin-selenium (ITS, 1X, Invitrogen, Carlsbad, CA); penicillin/streptomycin (1X, Invitrogen); 
fetal bovine serum (Invitrogen); amphotericin (Gibco Thermo Fisher Scientific, Gaithersburg, MD), and G418 
(Millipore-Sigma-EMD, Burlington, MA), (−)-quinpirole hydrochloride, (S)-(−)sulpiride, LiCl, bromocriptine 
mesylate, L-glutamine, HEPES, sodium pyruvate, and 2-mercaptoethanol.
Cell culture. Undifferentiated mouse cells were cultured from progenitor kidney cells isolated from mouse 
embryo kidneys following the procedure described by Woost et al.96; cells were kindly supplied by Dr. Ulrich 
Hopfer (Case Western Reserve School of Medicine, Cleveland, OH). These cells were differentiated into mature 
mouse renal proximal tubule cells (mRPTCs) and cultured to 60–70% confluence. mRPTCs were maintained 
in DMEM-F12 (Invitrogen) supplemented with fetal bovine serum (10%), penicillin/streptomycin (1X) and 
amphotericin (2.5 μg/ml). The mRPTCs were subsequently transfected with either vehicle (transfection reagent, 
Hyperfect, Qiagen, Valencia, CA), non-silencing AllStars Negative Control siRNA (20 nM, catalog#1027281, 
Qiagen) or mouse D2R siRNA (20 nM, catalog#SI04918410, Qiagen) and studied 72 hr post-transfection. For 
other experiments, mRPTCs were cultured to 90–95% confluence, serum-starved for 2 hr and treated for an addi-
tional 24 hr in serum-free medium with vehicle (PBS) or drug (1 μM quinpirole or 1 μM sulpiride).
Human renal proximal tubule cells (hRPTCs) were isolated from human kidney specimens obtained solely 
from male patients who had unilateral nephrectomy due to renal carcinoma or trauma. All samples were com-
pletely de-identified. Informed consent was obtained from all subjects for collection of these specimens. All pro-
cedures strictly followed the guidelines of a University of Virginia institutional review board-approved protocol, 
as well as the Declaration of Helsinki.
For isolation of the hRPTCs, only the healthy renal pole (as judged by visual and histological inspection) distal 
from the affected part of the kidney was used; cells were subsequently immortalized, as previously described97. 
Immortalized hRPTCs were maintained at 37°C, 5% CO2 and cultured to 90–95% confluence in non-polarizing 
conditions in DMEM-F12 (Invitrogen) containing (final concentrations): plasmocin (2.5 μg/ml), EGF (10 ng/
ml), dexamethasone (36 ng/ml), triiodothyronine (2 ng/ml), insulin-transferrin-selenium (ITS, 1X), penicillin/
streptomycin (1X), fetal bovine serum (2%), and G418 (0.4%). The hRPTCs were also genotyped for the presence 
of rs6276, rs6277 DRD2 SNPs. Four cell lines from subjects bearing rs6276 and rs6277 DRD2 SNP alleles as well 
as four control subjects without these SNPs (D2R-WT) were studied. These two SNPs occur within and adjacent 
to the DRD2 gene. Because of their close proximity, they are likely to be in linkage disequilibrium which limits 
the possibility of identifying cell lines bearing only one of the SNPs. hRPTCs were transfected with either vehicle 
(transfection reagent, Hyperfect, Qiagen, Valencia, CA), non-silencing AllStars Negative Control siRNA (20 nM; 
catalog#1027281, Qiagen), human D2R siRNA (20 nM; catalog#SI03076479, Qiagen), or human Wnt3a siRNA 
(20 nM; catalog#SI00145565, Qiagen) and studied 72 hr post-transfection.
To test the effects of Wnt/β-catenin pathway activation on D2R mRNA expression, hRPTCs were incubated 
in serum-free medium in the presence or absence of either recombinant Wnt3a protein (100 ng/ml, 24 hr) 
(catalog#G3154; LifeSpan Biosciences, Inc., Seattle, WA), LiCl (25 mM, 24 hr) or vehicle controls. mRNA was 
extracted from the respectively treated cells and cDNA was subsequently prepared as described below. Changes 
in D2R expression were measured by quantitative real-time PCR.
INS-1E cells (gift of Pierre Maechler, University of Geneva) were maintained in a humidified 37 °C incubator 
with 5% CO2. The cells were cultured as described earlier51 with RPMI 1640 media (Life Technologies, Norwalk, 
CT), supplemented with 5% (v/v) heat inactivated fetal bovine serum, 2 mM L-glutamine, 10 mM HEPES, 1 mM 
sodium pyruvate, 100 units/mL penicillin, 100 μg/mL streptomycin, and 50 μM 2-mercaptoethanol. The cells 
were subcultured weekly in a ratio of 1:5 to 1:10 with medium renewal every 3 to 4 days.
Preparation of Wnt3a-conditioned and L-cell control medium. Mouse fibroblast-derived L-Wnt3A 
cells (CRL-2647; ATCC, Manassas, VA) that stably express and secrete Wnt3a and the control untransfected 
parental L-Cell line (CRL-2648, ATCC) were purchased from ATCC (Manassas, VA). Control L-cells were cul-
tured in Dulbecco’s Modified Eagle’s Medium (Thermo Fisher Scientific) supplemented with 10% (v/v) fetal 
bovine serum. L-Wnt3A cells were supplemented with the same media as control L-cells along with the addition 
of 0.4 mg/ml G-418. Both cell lines were subcultured in a ratio of 1:10 with medium renewal every 2 to 3 days.
Transient transfection. hRPTCs were transfected with an empty vector or plasmid harboring wildtype 
human DRD2 under the control of cytomegalovirus promoter (RC202476; Origene Technologies, Inc., Rockville, 
MD), using the Fugene HD transfection reagent (E2311; Promega Corporation, Madison, WI) as per the manu-
facturer’s guidelines. Briefly, 4 μg of plasmid DNA were diluted to 400 μl with serum-free medium and mixed with 
16 μl of Fugene HD transfection. The transfection complex was incubated for 15 min at room temperature and 
added dropwise onto the cells in 10 cm tissue culture plates. Three days following transfection, the hRPTCs were 
harvested for protein extraction and immunoblotting, total RNA preparation, and RT-qPCR, or processed for 
immunofluorescence staining. Transfection efficiency was 40–45%. Transfections in INS-1E cells were performed 
using Lipofectamine 2000 transfection reagent (Invitrogen) overnight according to manufacturer instructions.
AAV vectors. To construct D2R AAV, a 1.7-kb human DRD2 cDNA from plasmid RC202476 (Origene 
Technologies Inc.) was excised as a KpnI and FseI fragment and inserted in between the same restriction sites 
within the pACS plasmid98. The control AAV (CAAV) vector, which does not encode any protein, contains an 
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EGFP cDNA in reverse orientation under the control of the CMV promoter. Recombinant AAV vector genomes 
were subsequently packaged into capsids from the AAV-9 serotype, via the triple transfection method in HEK 293 
cells, as described previously99,100.
TCF/LEF reporter assay. mRPTCs were treated with Drd2-specific siRNA (D2R siRNA; 20 nM, Qiagen) or 
non-silencing siRNA (NS siRNA; 20 nM, Qiagen). After 48 hr, the mRPTCs were trypsinized and seeded for transient 
reverse transfection with a TCF/LEF luciferase reporter provided by the Cignal Reporter Assay TCF/LEF luciferase 
reporter system (SABiosciences-Qiagen). Following transfection, the mRPTCs underwent drug treatment with either 
quinpirole (1 μM) or vehicle for 24 hr; acute sulpiride treatment (1 μM) was for 6 hr. Acute recombinant Wnt3a treat-
ment (LifeSpan Biosciences, Inc., Seattle, WA; 100 ng/ml) was for 2 hr. INS-1E cells were similarly reverse-transfected 
using the Cignal Reporter Assay TCF/LEF luciferase reporter system, followed by treatment with either RPMI 1640 or 
Wnt3a-conditioned medium, in the presence or absence of the D2R agonist bromocriptine (10 µM) for 18 hr.
RNA extraction and cDNA preparation. Kidney samples or cell lysates were homogenized, and total 
RNA was extracted with Trizol (Invitrogen, Carlsbad, CA) and further purified using the RNeasy RNA Extraction 
Mini kit (Qiagen). RNA samples were converted into first strand cDNA using an RT2 First Strand kit, following 
the manufacturer’s protocol (SABiosciences-Qiagen).
Quantitative Real-Time PCR. Total RNA was purified using the RNeasy Plus Mini kit (Qiagen, Valencia, 
CA). cDNA was prepared using an RT2 First Strand kit as per the manufacturer’s protocol (SABiosciences-Qiagen). 
Quantitative gene expression was analyzed by real-time PCR, performed on an ABI Prism 7900 HT (Thermo Fisher, 
Pittsburgh, PA). The assay used SYBR Green Real-Time PCR detection method (Qiagen) and all gene-specific 
primer assays were commercially available in the RT2 qPCR Primer Assay format, (SABiosciences-Qiagen) follow-
ing manufacturer’s instructions. Primers used were: MKi-67 (catalog#PPM03457B); Wnt3a (catalog#PPM04720C); 
D2R (catalog#PPM04288A); β-arrestin-2 (catalog#PPM04814G); Gapdh (catalog#PPM02946E); all primers were 
commercially available from Qiagen. Data were analyzed using the ΔΔCt method and expressed as fold-change 
relative to control101. In the case of quantitation of β-arrestin-2 expression in control mouse and human renal sam-
ples, we specifically measured mRNA levels in arbitrary units in order to directly compare β-arrestin-2 levels of 
expression relative to the Gapdh control (Supplementary Fig. S1).
Immunoblotting. Flash-frozen tissue homogenates and cell lysates were subjected to immunoblotting. The 
samples were homogenized or lysed in RIPA buffer, and equal amounts of protein (20 μg) were electrophoresed 
under reducing conditions on 4–20% gradient polyacrylamide gels and transferred onto nitrocellulose mem-
branes. The primary antibodies used were: anti-phospho-AKT (T308 phosphorylation site; catalog#13038, Cell 
Signaling Technology, Danvers, MA); anti-AKT (catalog#4685, Cell Signaling Technology); anti-phospho-GSK3β 
(S9 phosphorylation site; catalog#5558, Cell Signaling Technology); anti-GSK3β (catalog#9832, Cell Signaling 
Technology); anti-phospho-β-catenin (S675 phosphorylation site; catalog#4176, Cell Signaling Technology); 
anti-β-catenin (catalog#8480, Cell Signaling Technology); anti-D2R (catalog#AB5084P, Millipore Sigma); 
anti-Wnt3a (catalog#2391, Cell Signaling Technology); anti-Gapdh (catalog#AB2302, Sigma); anti-tubulin 
(catalog#ab6046, Abcam, Cambridge, MA). Results were normalized to Gapdh or tubulin and expressed as 
percentage- or fold-change, relative to the average signal intensity obtained from the respective controls.
Immunohistochemistry. The procedures for immunohistochemistry were described earlier4. Briefly, mouse 
kidneys were collected and fixed in 3.7% paraformaldehyde for 1-hr at 4°C. After washing in phosphate-buffered 
saline (3 times, 5 min each), the tissues were equilibrated with 30% sucrose in phosphate-buffered saline over-
night. Paraffin-embedded tissue sections were immunostained for expression of Wnt3a using a rabbit monoclonal 
anti-Wnt3a antibody (catalog#ab172612, Abcam). We stained for Ki-67, a marker of cell proliferation, using a rabbit 
polyclonal anti-Ki-67 antibody (catalog#ab15580, Abcam). We also stained for β-catenin using a goat polyclonal 
anti-β-catenin antibody (catalog#AF1329, R&D Systems, Minneapolis, MN). DAPI was used to visualize the nuclei 
of individual cells. Secondary antibodies included donkey anti-rabbit Alexa Fluor 555 (catalog#A-31572; Invitrogen) 
and a donkey anti-goat Alexa Fluor 488 (catalog#A-11055; Invitrogen). The cells were counted in at least 3 micros-
copy fields from each section at 10x magnification (n ≥ 3 per group). Confocal images of immunostained tissue were 
acquired at 20x magnification using a spinning disk confocal microscope (Zeiss, Thornwood, NY).
Cell proliferation assay. Cell proliferation was assessed using the Delfia Cell Proliferation kit (Caliper 
PerkinElmer Life Sciences, Waltham, MA). Approximately 1 × 104 cells were seeded into a 96-well Isoplate 
(PerkinElmer Life Sciences) and grown in complete media. Bromodeoxyuridine (BrdUrd, 10 μM) was added to the 
medium 24 hr prior to the end of the assay. The cells were subsequently fixed, the DNA was denatured, and the amount 
of incorporated BrdUrd was determined using an Eu-labeled monoclonal anti-BrdU antibody. Following formation 
of highly fluorescent chelates, fluorescent signal was detected by time-resolved fluorometry using a Victor3 multilabel 
reader (PerkinElmer Life Sciences). The same number of cells was seeded on a separate 96-well Isoplate and grown 
overnight before fixation with 4% paraformaldehyde and nuclear staining with DAPI. DAPI fluorescence was detected 
also using a Victor3 multilabel reader. Final results are reported as Eu fluorescence normalized to DAPI signal.
Animal procedures. All animals used in the study were C57BL/6 male mice (8–10 weeks old, weighing 
~20 g) which were purchased from The Jackson Laboratory (Bar Harbor, ME). All animals were housed and 
handled in accordance with all appropriate NIH guidelines. Our experimental protocol was approved by the 
institutional review board and ethics committee of George Washington University (IACUC protocol#A353). For 
all experiments, we abided by all relevant and appropriate animal care guidelines and regulations including the 
ARRIVE guidelines. All efforts were made to ameliorate animal suffering.
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In vivo siRNA treatments. Mice were anesthetized with an intraperitoneal injection of pentobarbital 
sodium (50 mg/kg) and placed in a supine position. The mice were treated with NS siRNA or D2R siRNA by sub-
capsular infusion (3 μg/day) using osmotic minipump (ALZET Osmotic Pumps, Cupertino, CA) for 28 days in 
the left kidney, leaving the contralateral kidney intact102. The siRNA was loaded into the osmotic minipump with 
a polyethylene tube connected to the osmotic minipump. The tube was inserted underneath the kidney capsule 
for continuous siRNA delivery. A detailed description of the protocols used was provided previously4.
Ureteral AAV infusions. For retrograde ureteral infusion of AAV vectors, 14 days following the initiation of 
siRNA treatment, the mice were anesthetized and operated on to expose the kidneys4. The distal ureteral portions 
closest to the bladder and the renal artery supplying the target kidney were clamped off using a microvenous clip. 
The ureter was punctured using a tuberculin syringe fitted with a 33-gauge needle and urine was gently aspirated 
out. A tuberculin syringe was placed into the ureter containing ~100 μl of the respective AAV vector (1 × 1011 
viral genome particles) and the solution was retrogradely infused into the ureter. The needle was withdrawn and 
a microvenous clip was placed proximal to the injection site on the ureter to prevent leakage and to attain max-
imum exposure to the infusion. Fifteen minutes later, the arterial and ureteral clips were sequentially removed, 
and the ureter was inspected for any evidence of leakage. The abdominal contents were replaced in reverse order 
and the incision site was closed.
Renal ischemia/reperfusion-injury model. The mice were anesthetized as above. Following exposure 
of the kidneys, both right and left renal vessels (artery and vein) were clamped with arterial clamps for 45 min to 
stop blood flow to both kidneys4. In control animals, while the kidneys were exposed, the right and left renal ves-
sels were not clamped. Upon clamp removal, a subset of the previously clamped mice were subjected to bilateral 
retrograde ureteral infusion of D2R AAV (experimental condition), as described above; the control group in this 
case consisted of clamped mice injected with control AAV (CAAV). The abdominal incision was closed, and the 
mice were allowed to recover. Fourteen days later, the mice were euthanized with an overdose of pentobarbital 
sodium (100 mg/kg). The kidneys, and other selected organs were harvested.
β-catenin and TCF/LEF binding site analysis. On the basis of the following sequence recognized by 
β-catenin and several TCF/LEF transcription factors (LEF1, TCF7, TCF7L1, TCF7L2): 5′-(A/T)(A/T)CAAAG-3′ 
(Wnt response element, WRE), we looked for conserved β-catenin-TCF/LEF binding sites upstream of WNT3A 
gene orthologs in 5 species that have an annotated WNT3A gene in the UCSC genome browser: Human (hg19), 
Mouse (mm10), Rat (rn6), Chicken (galGal5), and Zebrafish (danRer11). The 5-kb promoter region upstream 
of WNT3A TSS for each of the five species was searched for the eight possible WRE binding site sequences, 4 on 
each strand, in all available promoter isoform variants using a custom-made Python script. The same analysis 
was then extended to promoter regions 5-kb upstream of the DRD2 TSS, comparing the same five species for 
conserved binding sites: Human, Mouse, Rat, Chicken, and Zebrafish. Specifically, for the DRD2 ortholog in the 
danRer11 Zebrafish assembly, two different genes are listed in the UCSC genome browser: DRD2a and DRD2b. 
We found a conserved binding site corresponding to DRD2b which is reported in this study.
WNT3A promoter activity assay. WNT3A promoter activity was measured using the Secrete-Pair 
Dual Luminescence Assay System (GeneCopoeia, Rockville, MD). The plasmid pWT/Wnt3a/GLuc contains a 
1,721-base region from the human WNT3A promoter [−1635 to +86 of transcription start site (TSS)] driving 
the expression of naturally-secreted Gaussia luciferease (GLuc), and a secondary reporter with a CMV promoter 
driving the expression of secreted Alkaline Phosphatase (SEAP), serving as an internal control. The plasmid 
pMut/wnt3a/GLuc carries a mutation in which the conserved TCF/LEF binding site 5′-TTCAAAG-3′ at the 
position −1587 bases upstream of the TSS was mutated to 5′-CCGCGGT-3′. hRPTCs were co-transfected 
with NS siRNA (20 nM) or D2R siRNA (20 nM), and pWT/wnt3a/GLuc or pMut/wnt3a/GLuc. Two days later, 
hRPTCs were treated with fresh medium for 16 hr after which the cell culture supernatants were collected, and the 
luciferase activity measured via the Secrete-Pair Dual Luminescence Assay Kit (GeneCopoeia, Rockville, MD). 
Luciferase activity results were expressed as relative light units (RLUs) normalized to SEAP activity (RLUs/SEAP).
Phylogenetic tree analysis. We used the Wnt3a protein coding regions (exon sequences) of human, 
mouse, rat, chicken, and zebrafish species to construct a phylogenetic tree using the MEGA-7 software package. 
The evolutionary distances in the units of base substitutions per site were calculated using the maximum com-
posite likelihood method. There was a total of 1,052 positions after eliminating positions containing gaps and 
missing data. The phylogenetic tree was then constructed using the Neighbor-Joining method with the sum of 
branch lengths = 0.645.
Statistics. All results are expressed as mean ± SEM. Comparisons between experimental groups were per-
formed using Student’s t-tests for two groups or ANOVA followed by post-hoc Holm-Sidak analyses for more 
than two groups. All statistical analyses were performed using the GraphPad Prism software package (GraphPad 
Software, La Jolla, CA).
Data availability
The data and reagents generated and/or analyzed during the current study are available from the corresponding 
authors upon reasonable request.
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